fluorouracil has been researched along with Obesity in 27 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "After mastectomy, 265 postmenopausal patients with node-positive breast cancer were stratified according to pathologic nodal status and estrogen-receptor (ER) status and randomized to receive either 12 cycles of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP), or CMFP plus tamoxifen (CMFPT), or observation alone." | 9.05 | Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study. ( Bennett, JM; Carbone, PP; Cummings, F; Falkson, G; Kalish, LA; Olson, JE; Taylor, SG; Tormey, DC, 1985) |
| " The objective of this exploratory study was to examine the association of low skeletal muscle, commonly known as sarcopenia, on the pharmacokinetics (PKs) of 5-fluorouracil (5FU) in patients receiving FOLFOX for colorectal cancer." | 7.88 | The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. ( Choi, SK; Deal, AM; McLeod, HL; Muss, HB; O'Neil, B; Patel, JN; Sanoff, HK; Shachar, SS; Walko, CM; Weinberg, MS; Williams, GR, 2018) |
| "After intraperitoneal administration of carboplatin, each measured characteristics of bone marrow function was more significantly suppressed and the induced neutropenia was more serious in db/db mice than in the controls." | 7.81 | Myelotoxicity of carboplatin is increased in vivo in db/db mice, the animal model of obesity-associated diabetes mellitus. ( Aradi, J; Benkő, I; Géresi, K; Megyeri, A; Németh, J; Szabó, B; Szabó, Z, 2015) |
| " This study examines the effect of parameters reflecting the body size, body weight and height, body mass index (BMI), and body surface area (BSA) on the depth of the blood leukocyte nadir in breast cancer patients receiving adjuvant chemotherapy, when drug dosing was based on the BSA." | 5.31 | Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area. ( Blomqvist, C; Joensuu, H; Poikonen, P, 2001) |
| "Cancer and Leukemia Group B (CALGB) study 8541, a randomized study of schedule and dose of adjuvant cyclophosphamide, doxorubicin, and fluorouracil (CAF) for stage II breast cancer patients with positive regional lymph nodes, provided data on 1,435 women for analysis." | 5.08 | Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. ( Budman, DR; Hargis, JB; Henderson, IC; Hollis, DR; Rosner, GL; Schilsky, RL; Weiss, RB, 1996) |
| "After mastectomy, 265 postmenopausal patients with node-positive breast cancer were stratified according to pathologic nodal status and estrogen-receptor (ER) status and randomized to receive either 12 cycles of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP), or CMFP plus tamoxifen (CMFPT), or observation alone." | 5.05 | Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study. ( Bennett, JM; Carbone, PP; Cummings, F; Falkson, G; Kalish, LA; Olson, JE; Taylor, SG; Tormey, DC, 1985) |
| "Adipocytes differentiated in vitro promote DOX resistance (with cross-resistance to paclitaxel and 5-fluorouracil) in a large panel of human and murine breast cancer cell lines independently of their subtype." | 3.91 | Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP). ( Chaltiel, L; Clement, E; Dauvillier, S; Dumontet, C; Esteve, D; Fallone, F; Franchet, C; Geneste, A; Lazar, I; Le Gonidec, S; Lehuédé, C; Li, X; Longué, M; Muller, C; Nieto, L; Valet, P; Vaysse, C, 2019) |
| " The objective of this exploratory study was to examine the association of low skeletal muscle, commonly known as sarcopenia, on the pharmacokinetics (PKs) of 5-fluorouracil (5FU) in patients receiving FOLFOX for colorectal cancer." | 3.88 | The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. ( Choi, SK; Deal, AM; McLeod, HL; Muss, HB; O'Neil, B; Patel, JN; Sanoff, HK; Shachar, SS; Walko, CM; Weinberg, MS; Williams, GR, 2018) |
| "After intraperitoneal administration of carboplatin, each measured characteristics of bone marrow function was more significantly suppressed and the induced neutropenia was more serious in db/db mice than in the controls." | 3.81 | Myelotoxicity of carboplatin is increased in vivo in db/db mice, the animal model of obesity-associated diabetes mellitus. ( Aradi, J; Benkő, I; Géresi, K; Megyeri, A; Németh, J; Szabó, B; Szabó, Z, 2015) |
| "Obesity is associated with an increased risk of development and recurrence of colorectal cancer." | 2.76 | Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy. ( Derleyn, VA; Koopman, M; Mol, L; Muller, EW; Punt, CJ; Simkens, LH; Teerenstra, S; Ten Bokkel Huinink, D; Veldhuis, GJ, 2011) |
| "Obesity is a risk factor for the development of colon carcinoma." | 2.71 | Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. ( Benson, AB; Catalano, PJ; Fuchs, CS; Haller, DG; Macdonald, JS; Mayer, RJ; Meyerhardt, JA, 2003) |
| "Oxaliplatin utilized in colorectal neoplasms treatment could induce acute peripheral neuropathy (APN) which is a dreadful and frequent adverse event." | 1.91 | Incidence and risk factors associated with development of oxalipatin-induced acute peripheral neuropathy in colorectal cancer patients. ( Ben Ayed, W; Ben Mahmoud, IT; Ben Said, A; Berguiga, S; Cherif, I; Hamdi, A; Houij, R; Limayem, I, 2023) |
| " Full body surface areas-based dosing appears to be tolerated as well in obese as in lean women." | 1.40 | Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women. ( Carroll, JP; Cheng, ME; Fay, M; Martin, JH; Nguyen, L; Pillay, PS; Protani, MM; Saleem, M; Walpole, E, 2014) |
| "Obesity is a risk factor for the development of esophageal malignancy." | 1.37 | Esophageal adenocarcinoma after laparoscopic gastric band placement for obesity. ( Mathew, J; Odell, JA; Stauffer, JA, 2011) |
| "Obesity has been associated with both the carcinogenesis and poor prognosis of colon cancer, one of the leading causes of cancer-related death." | 1.37 | Insulin decreases therapeutic efficacy in colon cancer cell line HT29 via the activation of the PI3K/Akt pathway. ( Chen, J; Hu, C; Huang, XF; Katsifis, A, 2011) |
| "Obesity is associated with an increased risk of colon cancer." | 1.36 | Obesity is an independent prognostic variable in colon cancer survivors. ( Foster, NR; O'Connell, MJ; Rankin, C; Sargent, DJ; Sinicrope, FA, 2010) |
| " For both men and women, overweight and obese patients experience less toxicity associated with adjuvant chemoradiotherapy, suggesting that actual body weight dosing of fluorouracil for obese patients is justified." | 1.32 | Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. ( Benson, AB; Brady, D; Cummings, B; Fuchs, CS; Hollis, DR; Macdonald, JS; Mayer, RJ; McCollum, AD; Meyerhardt, JA; Niedzwiecki, D; O'Connell, MJ; Tepper, JE; Willett, C, 2004) |
| " This study examines the effect of parameters reflecting the body size, body weight and height, body mass index (BMI), and body surface area (BSA) on the depth of the blood leukocyte nadir in breast cancer patients receiving adjuvant chemotherapy, when drug dosing was based on the BSA." | 1.31 | Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area. ( Blomqvist, C; Joensuu, H; Poikonen, P, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.41) | 18.7374 |
| 1990's | 2 (7.41) | 18.2507 |
| 2000's | 3 (11.11) | 29.6817 |
| 2010's | 17 (62.96) | 24.3611 |
| 2020's | 3 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Ben Mahmoud, IT | 1 |
| Ben Said, A | 1 |
| Berguiga, S | 1 |
| Houij, R | 1 |
| Cherif, I | 1 |
| Hamdi, A | 1 |
| Ben Ayed, W | 1 |
| Limayem, I | 1 |
| VanderVeen, BN | 1 |
| Cardaci, TD | 1 |
| McDonald, SJ | 1 |
| Madero, SS | 1 |
| Unger, CA | 1 |
| Bullard, BM | 1 |
| Enos, RT | 1 |
| Velázquez, KT | 1 |
| Kubinak, JL | 1 |
| Fan, D | 1 |
| Murphy, EA | 1 |
| Harada, K | 1 |
| Yahata, T | 1 |
| Onizuka, M | 1 |
| Ibrahim, AA | 1 |
| Kikkawa, E | 1 |
| Miyata, T | 1 |
| Ando, K | 1 |
| Williams, GR | 1 |
| Deal, AM | 1 |
| Shachar, SS | 1 |
| Walko, CM | 1 |
| Patel, JN | 1 |
| O'Neil, B | 1 |
| McLeod, HL | 1 |
| Weinberg, MS | 1 |
| Choi, SK | 1 |
| Muss, HB | 1 |
| Sanoff, HK | 1 |
| Miyamoto, Y | 1 |
| Oki, E | 1 |
| Emi, Y | 1 |
| Tokunaga, S | 1 |
| Shimokawa, M | 1 |
| Ogata, Y | 1 |
| Akagi, Y | 1 |
| Sakamoto, Y | 1 |
| Tanaka, T | 1 |
| Saeki, H | 1 |
| Maehara, Y | 1 |
| Baba, H | 1 |
| Li, Y | 1 |
| Zhu, S | 1 |
| Zhang, Y | 1 |
| Liu, T | 1 |
| Su, L | 1 |
| Zhang, Q | 1 |
| Luo, Y | 1 |
| Lehuédé, C | 1 |
| Li, X | 1 |
| Dauvillier, S | 1 |
| Vaysse, C | 1 |
| Franchet, C | 1 |
| Clement, E | 1 |
| Esteve, D | 1 |
| Longué, M | 1 |
| Chaltiel, L | 1 |
| Le Gonidec, S | 1 |
| Lazar, I | 1 |
| Geneste, A | 1 |
| Dumontet, C | 1 |
| Valet, P | 1 |
| Nieto, L | 1 |
| Fallone, F | 1 |
| Muller, C | 1 |
| Lamberth, F | 1 |
| Guilbert, P | 1 |
| Gaillot-Petit, N | 1 |
| Champagne, C | 1 |
| Looten-Vieren, L | 1 |
| Nguyen, TD | 1 |
| Ladoire, S | 1 |
| Dalban, C | 1 |
| Roché, H | 1 |
| Spielmann, M | 1 |
| Fumoleau, P | 1 |
| Levy, C | 1 |
| Martin, AL | 1 |
| Ecarnot, F | 1 |
| Bonnetain, F | 1 |
| Ghiringhelli, F | 1 |
| Carroll, JP | 1 |
| Protani, MM | 1 |
| Nguyen, L | 1 |
| Cheng, ME | 1 |
| Fay, M | 1 |
| Saleem, M | 1 |
| Pillay, PS | 1 |
| Walpole, E | 1 |
| Martin, JH | 1 |
| Cihan, YB | 1 |
| Jung, HW | 1 |
| Kim, JW | 1 |
| Kim, JY | 1 |
| Kim, SW | 1 |
| Yang, HK | 1 |
| Lee, JW | 1 |
| Lee, KW | 1 |
| Kim, DW | 1 |
| Kang, SB | 1 |
| Kim, KI | 1 |
| Kim, CH | 1 |
| Kim, JH | 1 |
| Géresi, K | 1 |
| Megyeri, A | 1 |
| Szabó, B | 1 |
| Szabó, Z | 1 |
| Aradi, J | 1 |
| Németh, J | 1 |
| Benkő, I | 1 |
| Gennari, A | 1 |
| Amadori, D | 1 |
| Scarpi, E | 1 |
| Farolfi, A | 1 |
| Paradiso, A | 1 |
| Mangia, A | 1 |
| Biglia, N | 1 |
| Gianni, L | 1 |
| Tienghi, A | 1 |
| Rocca, A | 1 |
| Maltoni, R | 1 |
| Antonucci, G | 1 |
| Bruzzi, P | 1 |
| Nanni, O | 1 |
| Sinicrope, FA | 1 |
| Foster, NR | 1 |
| Sargent, DJ | 1 |
| O'Connell, MJ | 2 |
| Rankin, C | 1 |
| Bartucci, M | 1 |
| Svensson, S | 1 |
| Ricci-Vitiani, L | 1 |
| Dattilo, R | 1 |
| Biffoni, M | 1 |
| Signore, M | 1 |
| Ferla, R | 1 |
| De Maria, R | 1 |
| Surmacz, E | 1 |
| Stauffer, JA | 1 |
| Mathew, J | 1 |
| Odell, JA | 1 |
| Chen, J | 1 |
| Katsifis, A | 1 |
| Hu, C | 1 |
| Huang, XF | 1 |
| Simkens, LH | 1 |
| Koopman, M | 1 |
| Mol, L | 1 |
| Veldhuis, GJ | 1 |
| Ten Bokkel Huinink, D | 1 |
| Muller, EW | 1 |
| Derleyn, VA | 1 |
| Teerenstra, S | 1 |
| Punt, CJ | 1 |
| Legge, F | 1 |
| Margariti, PA | 1 |
| Lucidi, A | 1 |
| Macchia, G | 1 |
| Petrillo, M | 1 |
| Iannone, V | 1 |
| Carone, V | 1 |
| Morganti, AG | 1 |
| Scambia, G | 1 |
| Ferrandina, G | 1 |
| Meyerhardt, JA | 2 |
| Catalano, PJ | 1 |
| Haller, DG | 1 |
| Mayer, RJ | 2 |
| Benson, AB | 2 |
| Macdonald, JS | 2 |
| Fuchs, CS | 2 |
| Tepper, JE | 1 |
| Niedzwiecki, D | 1 |
| Hollis, DR | 2 |
| McCollum, AD | 1 |
| Brady, D | 1 |
| Cummings, B | 1 |
| Willett, C | 1 |
| Rosner, GL | 1 |
| Hargis, JB | 1 |
| Budman, DR | 1 |
| Weiss, RB | 1 |
| Henderson, IC | 1 |
| Schilsky, RL | 1 |
| Poikonen, P | 1 |
| Blomqvist, C | 1 |
| Joensuu, H | 1 |
| Mehta, RR | 1 |
| Beattie, CW | 1 |
| Das Gupta, TK | 1 |
| Powis, G | 1 |
| Reece, P | 1 |
| Ahmann, DL | 1 |
| Ingle, JN | 1 |
| Taylor, SG | 1 |
| Kalish, LA | 1 |
| Olson, JE | 1 |
| Cummings, F | 1 |
| Bennett, JM | 1 |
| Falkson, G | 1 |
| Tormey, DC | 1 |
| Carbone, PP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab[NCT01164215] | Phase 1 | 76 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| The Effect of Nutrition for the Colorectal Cancer Patients Receiving Chemotherapy-randomized Controlled Study[NCT04567459] | 100 participants (Anticipated) | Interventional | 2021-01-27 | Recruiting | |||
| Cetuximab Added to Capecitabine, Oxaliplatin and Bevacizumab in Patients With Previously Untreated Advanced Colorectal Carcinoma, a Randomised Phase III Study[NCT00208546] | Phase 3 | 750 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Evaluation of Eating Habits and Dysgeusia During Chemotherapy Treatment: a Prospective Cohort Study on Patients Affected by Breast Cancer[NCT03210441] | 204 participants (Anticipated) | Observational | 2014-05-06 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 trials available for fluorouracil and Obesity
| Article | Year |
|---|---|
Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: a pooled analysis of two randomised trials.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Body M | 2014 |
Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Breast Neoplasms; Chem | 2016 |
Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Cam | 2011 |
Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Weight; Chemotherapy, Adjuvant | 2003 |
Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Chemotherapy, Adjuvan | 1996 |
Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; | 1987 |
Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1985 |
20 other studies available for fluorouracil and Obesity
| Article | Year |
|---|---|
Incidence and risk factors associated with development of oxalipatin-induced acute peripheral neuropathy in colorectal cancer patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou | 2023 |
Obesity reduced survival with 5-fluorouracil and did not protect against chemotherapy-induced cachexia or immune cell cytotoxicity in mice.
Topics: Animals; Antineoplastic Agents; Cachexia; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Mice; Ne | 2022 |
Plasminogen activator inhibitor type-1 is a negative regulator of hematopoietic regeneration in the adipocyte-rich bone marrow microenvironment.
Topics: Adipocytes; Animals; Antimetabolites; Bone Marrow; Fluorouracil; Gene Knockout Techniques; Hematopoi | 2021 |
The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizuma | 2018 |
Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; B | 2018 |
High fat diet-induced obesity exacerbates hematopoiesis deficiency and cytopenia caused by 5-fluorouracil via peroxisome proliferator-activated receptor γ.
Topics: Animals; Bone Marrow; Bone Marrow Diseases; Dietary Fats; Flow Cytometry; Fluorouracil; Hematopoiesi | 2018 |
Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP).
Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Adult; Aged; Animals; Antineoplastic Agents; Breast; Breast N | 2019 |
[Potential indications for helical tomotherapy in breast cancers].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2014 |
Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; | 2014 |
Relationship of body mass index with prognosis in breast cancer patients treated with adjuvant radiotherapy and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Ch | 2015 |
Myelotoxicity of carboplatin is increased in vivo in db/db mice, the animal model of obesity-associated diabetes mellitus.
Topics: Animals; Antineoplastic Agents; Bone Marrow Diseases; Carboplatin; Diabetes Mellitus, Experimental; | 2015 |
Obesity is an independent prognostic variable in colon cancer survivors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Composition; Body | 2010 |
Obesity hormone leptin induces growth and interferes with the cytotoxic effects of 5-fluorouracil in colorectal tumor stem cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Adhesion; Cel | 2010 |
Esophageal adenocarcinoma after laparoscopic gastric band placement for obesity.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bariatric Surgery; Deglutition | 2011 |
Insulin decreases therapeutic efficacy in colon cancer cell line HT29 via the activation of the PI3K/Akt pathway.
Topics: Antineoplastic Agents; Cell Survival; Chromones; Colonic Neoplasms; Cycloheximide; Dose-Response Rel | 2011 |
Completion surgery after concomitant chemoradiation in obese women with locally advanced cervical cancer: Evaluation of toxicity and outcome measures.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Disease-Free Su | 2013 |
Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Chemotherapy | 2004 |
Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Constitution; Body Mass Index; Bod | 2001 |
Endocrine profile in breast cancer patients receiving chemotherapy.
Topics: Adult; Age Factors; Amenorrhea; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Bre | 1992 |